This trial is looking at how well two medicines, durvalumab and domvanalimab, work together after patients receive certain types of radiation and chemotherapy. It focuses on adults with locally advanced non-small cell lung cancer (NSCLC) that cannot be surgically removed. The main goal is to check how effective and safe this combination is for keeping the cancer under control.
The trial's ID number is NCT05211895. It is a Phase 3 study, which means the trial is testing how well the treatment works and how safe it is. The trial is FDA-regulated and plans to include about 860 participants.
Who can join
Adults aged 18 and older can join this study. It is open to men and women who have been treated for Stage III NSCLC and have not seen their cancer progress after treatment. The trial team will confirm if you meet all the requirements.
Condition
Non-Small Cell Lung Cancer
Age group
Adult, Older adult
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly assigned to one of two groups. One group will receive durvalumab and domvanalimab together, while the other group will get durvalumab with a placebo (a treatment that looks like the real medicine but has no active ingredients). Everyone will receive their treatment through an IV infusion every four weeks for up to a year.
Where
This trial is enrolling at 43 locations. Recruiting sites are listed first.
Chief of Thoracic Surgery and Director of the Lung Cancer Program at West Virginia University Cancer Institute. Treats lung cancer and esophageal cancer.
Treats pancreatic cancer, lung cancer and colorectal cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Led the National Lung Screening Trial. Treats lung cancer. Other doctors who help with cancer care, like gastroenterologists, dermatologists, and endocrinologists. Recognized at state, national or international level.